Search

 
 
 
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

BIO ROUNDUP: $74B FOR CELGENE, TWO CAR-T TALES, READY FOR SF & MORE

In 2018, my Exome colleagues and I published hundreds of stories about health, medicine, the biopharma industry, government policy,...

 
 
 
Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More

BIO ROUNDUP: 2019 TRIALS, PILGRIM PRICE CHAT, PRE-XMAS SALES & MORE

It's beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather....

15 For '19: Key Clinical Data to Watch For Next Year

15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR

On Monday, Xconomy began our annual look ahead at clinical trials that could define biotech and have profound healthcare effects in...

 
 
 
Imfinzi looks flimsy in AstraZeneca's Phase III head and neck cancer study

IMFINZI LOOKS FLIMSY IN ASTRAZENECA'S PHASE III HEAD AND NECK CANCER STUDY

Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after...

Bio Roundup: Moderna's IPO, Arena's Comeback, E-Cig Survey & More

BIO ROUNDUP: MODERNA'S IPO, ARENA'S COMEBACK, E-CIG SURVEY & MORE

Thanksgiving is around the corner and this week delivered a bounty of deals that have a number of life science companies expressing...

 
 
 
Medisafe to Get Paid For Health App's Performance

MEDISAFE TO GET PAID FOR HEALTH APP'S PERFORMANCE

More technology startups are embracing the healthcare industry's increasing willingness to pay for products based on how much they...

 
 
 

ESMO18: MERCK'S STING AGONIST LACKS BITE ON ITS OWN

Amid high expectations, the first clinical data with Merck & Co's STING agonist at ESMO has proved a disappointment-at least as a monotherapy.

 
 
 
Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive's End

BIO ROUNDUP: PRICES ON TV, NOVARTIS HEARTS RADIO, WARP DRIVE'S END

Two new battlegrounds emerged this week in the nation's ongoing drug pricing debate. The first involved television: The federal government...

 
 
 
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant's IPO & More

BIO ROUNDUP: NOBEL PRIZES, DUCHENNE STEPS, GUARDANT'S IPO & MORE

Cancer immunotherapy is all the rage these days. The idea of harnessing the immune system to treat cancer has sparked billions of dollars...

 
 
 

DRAGONFLY THERAPEUTICS IN $695M CANCER R&D PACT WITH MERCK

More than a year after the insect-inspired biotech Dragonfly Therapeutics penned a blood cancer pact with Big Biotech Celgene, it's...

Bio Roundup: Amarin's Stunner, Lung Cancer News, Data Dumps & More

BIO ROUNDUP: AMARIN'S STUNNER, LUNG CANCER NEWS, DATA DUMPS & MORE

Six years ago, a biotech called Amarin won FDA approval of a prescription fish-oil pill, Vascepa, because it could lower triglycerides,...

 
 
 
Merck's board just changed the rules to keep its CEO on board after he turns 65

MERCK'S BOARD JUST CHANGED THE RULES TO KEEP ITS CEO ON BOARD AFTER HE TURNS 65

Merck CEO Kenneth Frazier plans to stay on in his role as CEO past December 2019, when he turns 65. The pharma giant's board of directors...

FORMER MERCK CLINICAL RESEARCH VP ARTHUR SANTORA JOINS ENTERA BIO AS CMO

Former Merck clinical research leader Arthur Santora, M.D., Ph.D., is coming out of retirement to serve as the new chief medical officer...